Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193557 · ClinicalTrials.gov registry record · Phase 2
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00193557 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 40 participants.
The verdict
NCT00193557, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezomib is effective in producing responses in patients with stable disease or progression after weekly bortezomib
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193557
The ClinicalTrials.gov registry entry for NCT00193557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT00193557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193557 about?
NCT00193557 is a clinical study titled "Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma". This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezomib is effective in producing responses in patients with stable disease or progression after weekly b...
What is the current status of trial NCT00193557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00193557?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00193557?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.